Associations consistent across different psychiatric conditions, for Alzheimer disease and all other dementias
Announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year
The Self-Administered Gerocognitive Examination detects the conversion from mild cognitive impairment to dementia sooner than the MMSE
Drug shows promise in clearing brain plaques believed to play a role in Alzheimer disease
Amyloid-related imaging abnormalities-edema seen on brain MRI most common adverse event in participants receiving high-dose aducanumab
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid
Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health
In randomized, double-blind trial, no difference seen in scores for agitated behaviors at 12 weeks with mirtazapine versus placebo
Does not improve primary outcome, but did improve performance on certain cognitive tasks in those with epileptiform activity
Overall, 92.2, 91.0, and 85.5 percent of Medicare beneficiaries with ADRDs, Alzheimer disease, and MCI met at least one of the exclusion criteria